{"id":"https://openalex.org/W2011393181","doi":"https://doi.org/10.1016/j.ophtha.2011.12.016","title":"HORIZON: An Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration","display_name":"HORIZON: An Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration","publication_year":2012,"publication_date":"2012-02-04","ids":{"openalex":"https://openalex.org/W2011393181","doi":"https://doi.org/10.1016/j.ophtha.2011.12.016","mag":"2011393181","pmid":"https://pubmed.ncbi.nlm.nih.gov/22306121"},"language":"en","primary_location":{"id":"doi:10.1016/j.ophtha.2011.12.016","doi":"https://doi.org/10.1016/j.ophtha.2011.12.016","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.ophtha.2011.12.016","pdf_url":null,"source":{"id":"https://openalex.org/S207341048","display_name":"Ophthalmology","issn_l":"0161-6420","issn":["0161-6420","1549-4713"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Ophthalmology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5027046934","display_name":"Michael A. Singer","orcid":"https://orcid.org/0000-0002-0149-4802","observed_orcids":["https://orcid.org/0000-0002-0149-4802"]},"institutions":[{"id":"https://openalex.org/I4210092901","display_name":"Medical Center Ophthalmology Associates","ror":"https://ror.org/00jfvgs31","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210092901"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Michael A. Singer","raw_affiliation_strings":["Medical Center Ophthalmology Associates, San Antonio, Texas 78240, USA. msinger@mcoaeyecare.com","Medical Center Ophthalmology Associates, San Antonio, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Center Ophthalmology Associates, San Antonio, Texas 78240, USA. msinger@mcoaeyecare.com","institution_ids":["https://openalex.org/I4210092901"]},{"raw_affiliation_string":"Medical Center Ophthalmology Associates, San Antonio, Texas","institution_ids":["https://openalex.org/I4210092901"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113479093","display_name":"Carl C. Awh","orcid":"https://orcid.org/0000-0002-1355-9722","observed_orcids":["https://orcid.org/0000-0002-1355-9722"]},"institutions":[{"id":"https://openalex.org/I4210158047","display_name":"Tennessee Retina","ror":"https://ror.org/055papc77","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210158047"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Carl C. Awh","raw_affiliation_strings":["Tennessee Retina, Nashville, Tennessee"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tennessee Retina, Nashville, Tennessee","institution_ids":["https://openalex.org/I4210158047"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014881844","display_name":"Srinivas Reddy Sadda","orcid":"https://orcid.org/0000-0002-4939-3306","observed_orcids":["https://orcid.org/0000-0002-4939-3306"]},"institutions":[{"id":"https://openalex.org/I4210095445","display_name":"Doheny Eye Institute","ror":"https://ror.org/00qvx5329","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210095445"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"SriniVas Sadda","raw_affiliation_strings":["Doheny Eye Institute, Los Angeles, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Doheny Eye Institute, Los Angeles, California","institution_ids":["https://openalex.org/I4210095445"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101974690","display_name":"William R. Freeman","orcid":"https://orcid.org/0000-0001-6382-1218","observed_orcids":["https://orcid.org/0000-0001-6382-1218","https://orcid.org/0000-0001-9979-2500"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William R. Freeman","raw_affiliation_strings":["University of California at San Diego, Jacobs Retina Center, La Jolla, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of California at San Diego, Jacobs Retina Center, La Jolla, California","institution_ids":["https://openalex.org/I36258959"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113178090","display_name":"Andrew N. Antoszyk","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165427","display_name":"Charlotte Eye Ear Nose & Throat Associates","ror":"https://ror.org/05fwfqf82","country_code":"US","type":"other","lineage":["https://openalex.org/I4210165427"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew N. Antoszyk","raw_affiliation_strings":["Charlotte Eye, Ear, Nose and Throat Associates, Charlotte, North Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Charlotte Eye, Ear, Nose and Throat Associates, Charlotte, North Carolina","institution_ids":["https://openalex.org/I4210165427"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062954288","display_name":"Pamela Wong","orcid":"https://orcid.org/0000-0003-2843-2289","observed_orcids":["https://orcid.org/0000-0003-2843-2289"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pamela Wong","raw_affiliation_strings":["Genentech, Inc., South San Francisco, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, California","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"last","author":{"id":null,"display_name":"Lisa Tuomi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lisa Tuomi","raw_affiliation_strings":["Genentech, Inc., South San Francisco, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, California","institution_ids":["https://openalex.org/I183934855"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":6,"corresponding_author_ids":["https://openalex.org/A5027046934"],"corresponding_institution_ids":["https://openalex.org/I4210092901"],"apc_list":{"value":4990,"currency":"USD","value_usd":4990},"apc_paid":null,"fwci":30.2062,"has_fulltext":false,"cited_by_count":361,"citation_normalized_percentile":{"value":0.99907096,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":99,"max":100},"biblio":{"volume":"119","issue":"6","first_page":"1175","last_page":"1183"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.9945999979972839,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.9945999979972839,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11377","display_name":"Retinal and Macular Surgery","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11194","display_name":"Ocular Diseases and Beh\u00e7et\u2019s Syndrome","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ranibizumab","display_name":"ranibizumab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/choroidal-neovascularization","display_name":"choroidal neovascularization","score":0.9919999837875366},{"id":"https://openalex.org/keywords/age-related-macular-degeneration","display_name":"age-related macular degeneration","score":0.9990000128746033},{"id":"https://openalex.org/keywords/intravitreal-injection","display_name":"intravitreal injection","score":0.8100000023841858},{"id":"https://openalex.org/keywords/long-term-safety","display_name":"long-term safety","score":0.7620000243186951},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.8840000033378601},{"id":"https://openalex.org/keywords/endophthalmitis","display_name":"endophthalmitis","score":0.9409999847412109},{"id":"https://openalex.org/keywords/intraocular-pressure","display_name":"intraocular pressure","score":0.949999988079071},{"id":"https://openalex.org/keywords/glaucoma","display_name":"glaucoma","score":0.9580000042915344},{"id":"https://openalex.org/keywords/cataract","display_name":"cataract","score":0.9829999804496765},{"id":"https://openalex.org/keywords/visual-acuity","display_name":"visual acuity","score":0.7419999837875366},{"id":"https://openalex.org/keywords/anti-vegf-therapy","display_name":"anti-VEGF therapy","score":0.7850000262260437},{"id":"https://openalex.org/keywords/horizon-trial","display_name":"HORIZON trial","score":0.6600000262260437},{"id":"https://openalex.org/keywords/lens-damage","display_name":"lens damage","score":0.6299999952316284},{"id":"https://openalex.org/keywords/retinal-tears","display_name":"retinal tears","score":0.7929999828338623},{"id":"https://openalex.org/keywords/retinal-detachment","display_name":"retinal detachment","score":0.7400000095367432}],"concepts":[{"id":"https://openalex.org/C2781100027","wikidata":"https://www.wikidata.org/wiki/Q414270","display_name":"Ranibizumab","level":4,"score":0.9906600117683411},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9442857503890991},{"id":"https://openalex.org/C2776403814","wikidata":"https://www.wikidata.org/wiki/Q27429789","display_name":"Macular degeneration","level":2,"score":0.7502249479293823},{"id":"https://openalex.org/C118487528","wikidata":"https://www.wikidata.org/wiki/Q161437","display_name":"Ophthalmology","level":1,"score":0.7432836294174194},{"id":"https://openalex.org/C2781359195","wikidata":"https://www.wikidata.org/wiki/Q5105209","display_name":"Choroidal neovascularization","level":3,"score":0.5663467049598694},{"id":"https://openalex.org/C2778257484","wikidata":"https://www.wikidata.org/wiki/Q555066","display_name":"Visual acuity","level":2,"score":0.5331052541732788},{"id":"https://openalex.org/C2777235844","wikidata":"https://www.wikidata.org/wiki/Q1294912","display_name":"Endophthalmitis","level":2,"score":0.49027493596076965},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.44854918122291565},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.41605108976364136},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.3351733684539795},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.33315378427505493},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.18361249566078186},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.07703295350074768}],"mesh":[{"descriptor_ui":"D000069579","descriptor_name":"Ranibizumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008268","descriptor_name":"Macular Degeneration","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D008268","descriptor_name":"Macular Degeneration","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008268","descriptor_name":"Macular Degeneration","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014792","descriptor_name":"Visual Acuity","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020256","descriptor_name":"Choroidal Neovascularization","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D020256","descriptor_name":"Choroidal Neovascularization","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D020256","descriptor_name":"Choroidal Neovascularization","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D042461","descriptor_name":"Vascular Endothelial Growth Factor A","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D058449","descriptor_name":"Intravitreal Injections","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.ophtha.2011.12.016","doi":"https://doi.org/10.1016/j.ophtha.2011.12.016","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.ophtha.2011.12.016","pdf_url":null,"source":{"id":"https://openalex.org/S207341048","display_name":"Ophthalmology","issn_l":"0161-6420","issn":["0161-6420","1549-4713"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Ophthalmology","raw_type":"journal-article"},{"id":"pmid:22306121","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22306121","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Ophthalmology","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":11,"referenced_works":["https://openalex.org/W1481978003","https://openalex.org/W1696340081","https://openalex.org/W1987699263","https://openalex.org/W2012906786","https://openalex.org/W2068742492","https://openalex.org/W2075984382","https://openalex.org/W2085712747","https://openalex.org/W2085752173","https://openalex.org/W2091989599","https://openalex.org/W2124415048","https://openalex.org/W4239471829"],"related_works":["https://openalex.org/W1513613431","https://openalex.org/W1976685144","https://openalex.org/W2052006575","https://openalex.org/W4405671211","https://openalex.org/W2124415048","https://openalex.org/W1966486839","https://openalex.org/W2081273617","https://openalex.org/W2990113520","https://openalex.org/W2317436115","https://openalex.org/W2333161755"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":7},{"year":2025,"cited_by_count":9},{"year":2024,"cited_by_count":17},{"year":2023,"cited_by_count":10},{"year":2022,"cited_by_count":24},{"year":2021,"cited_by_count":27},{"year":2020,"cited_by_count":38},{"year":2019,"cited_by_count":34},{"year":2018,"cited_by_count":23},{"year":2017,"cited_by_count":34},{"year":2016,"cited_by_count":30},{"year":2015,"cited_by_count":31},{"year":2014,"cited_by_count":37},{"year":2013,"cited_by_count":29},{"year":2012,"cited_by_count":10}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}